What it's for (Indications)
- Carboplatin, a platinum-based antineoplastic agent (e.
- g.
- , Pharmaplatin), is indicated for the treatment of various malignancies, often administered as part of combination chemotherapy regimens.
- Its primary indication includes advanced ovarian carcinoma of epithelial origin, where it is used for the initial treatment of patients with optimally or suboptimally debulked tumors, and for palliative treatment of patients with recurrent ovarian carcinoma previously treated with other chemotherapy.
- Furthermore, carboplatin is widely utilized in the management of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), typically in combination with other cytotoxic agents to enhance therapeutic efficacy.
- It also plays a role in the treatment of germ cell tumors, bladder cancer, and certain head and neck cancers, particularly nasopharyngeal carcinoma, reflecting its broad spectrum of activity against rapidly dividing cancer cells.
- The selection of carboplatin for a specific indication depends on the tumor type, stage, patient's overall health, and the potential for combination therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Carboplatin dosing is highly individualized and primarily guided by the patient's renal function, with the most common method employing the Calvert formula: Total Dose (mg) = Target AUC x (GFR + 25). The target Area Under the Curve (AUC) typically ranges from 4 to 7 mg*min/mL, depending on the specific malignancy, whether it's used as a single agent or in combination therapy, and the desired intensity of myelosuppression. For example, an AUC of 5-6 mg*min/mL is often targeted for ovarian cancer in combination with paclitaxel. Glomerular Filtration Rate (GFR) is usually estimated using methods such as the Cockcroft-Gault formula or measured creatinine clearance. Carboplatin is administered as an intravenous infusion over 15 minutes to 1 hour, typically once every 3 to 4 weeks. Doses must be carefully adjusted based on nadir blood counts from previous cycles, particularly platelet and neutrophil counts, to mitigate severe myelosuppression. Pre-medication with antiemetics is standard to manage potential nausea and vomiting. Dosage modifications are also necessary for patients with impaired renal function, as carboplatin is primarily eliminated via the kidneys, to prevent increased toxicity. |
Safety & Warnings
Common Side Effects
- Carboplatin therapy is associated with a range of side effects, with myelosuppression being the most common and dose-limiting toxicity.
- This manifests as thrombocytopenia, leukopenia, neutropenia, and anemia, with platelet nadir typically occurring between days 14 and 21 after administration.
- Gastrointestinal toxicities are frequent, including moderate to severe nausea and vomiting, which are often managed with prophylactic antiemetics, as well as mucositis, diarrhea, and constipation.
- While less neurotoxic than cisplatin, peripheral neuropathy (e.
- g.
- , paresthesias, decreased deep tendon reflexes) can occur, especially with cumulative doses.
- Ototoxicity, characterized by tinnitus or hearing loss, is generally mild but requires monitoring in susceptible patients.
- Nephrotoxicity is less pronounced compared to cisplatin, but monitoring of renal function remains important.
- Hypersensitivity reactions, ranging from rash and pruritus to severe anaphylaxis, can occur, particularly after multiple cycles and often in patients previously exposed to platinum compounds.
- Other potential side effects include fatigue, transient elevations in liver enzymes, and alopecia (which is less common and less severe than with many other chemotherapeutic agents).
Serious Warnings
- Black Box Warning: Carboplatin Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect.
- Several critical warnings are associated with carboplatin administration due to its potent cytotoxic nature.
- Severe myelosuppression, particularly thrombocytopenia and neutropenia, is the primary dose-limiting toxicity and necessitates vigilant monitoring of complete blood counts (CBC) before each cycle and weekly during treatment.
- Dose reductions or delays are often required to manage hematological toxicities.
- Patients should be closely observed for hypersensitivity reactions, which can manifest as rash, fever, bronchospasm, and hypotension, potentially leading to anaphylaxis, especially with repeated exposure to platinum compounds.
- Emergency resuscitation equipment and personnel should be immediately available during administration.
- Renal impairment necessitates careful dosage adjustments, as carboplatin is primarily cleared by the kidneys, and pre-existing renal dysfunction can significantly increase toxicity.
- While less severe than with cisplatin, peripheral neuropathy and ototoxicity can occur, especially with cumulative doses, warranting neurological and audiological assessments as clinically indicated.
- Carboplatin is teratogenic and can cause fetal harm when administered to pregnant women; therefore, effective contraception must be used by women of childbearing potential during and for a period after treatment.
- Breastfeeding is contraindicated.
- Extravasation should be avoided, and the infusion site closely monitored for signs of irritation, though carboplatin is generally not considered a vesicant.
How it Works (Mechanism of Action)
Carboplatin exerts its cytotoxic effects by acting as an alkylating-like agent, fundamentally interfering with DNA structure and function in rapidly dividing cells, particularly cancer cells. As a platinum coordination complex, it undergoes aquation in the intracellular environment, leading to the formation of highly reactive platinum species. These activated species then covalently bind to nucleophilic sites on DNA, predominantly at the N7 position of guanine residues. This binding results in the formation of intra-strand and inter-strand DNA cross-links, as well as DNA-protein cross-links. These cross-links are critical in preventing key cellular processes such as DNA replication and transcription, effectively halting the cell cycle, primarily in the G2 phase. The inability of the cell to repair this extensive DNA damage ultimately triggers programmed cell death (apoptosis). While its mechanism is similar to cisplatin, carboplatin's different leaving group (cyclobutane dicarboxylate) contributes to its distinct pharmacological profile, including lower nephrotoxicity and ototoxicity but a greater degree of myelosuppression, making it a valuable alternative in various chemotherapy regimens.